03 nov: Deducta købt af investeringsselskab
05 nov: Maskulin luksusmad fra Mols kro
04-11-2010 07:30:45

Dräger remains on path to success

Drägerwerk AG & Co. KGaA /

Dräger remains on path to success

Processed and transmitted by Thomson Reuters.

The issuer is solely responsible for the content of this announcement.

  • Significant rise in order intake, net sales and EBIT
  • Equity ratio at 32.4 percent
  • Company expects best fiscal year on record

 

Lübeck - Drägerwerk AG & Co. KGaA continued to develop extremely well in the third quarter of 2010 and again increased its net sales and earnings forecasts for the entire fiscal year on October 13. In the first nine months of 2010, order intake rose by 6.8 percent (net of currency effects) year-on-year to EUR 1,568.4 million. Orders on hand remained almost the same as in prior year with EUR 478.6 million, dropping by just 0.4 percent (net of currency effects). Net sales went up by 10.2 percent (net of currency effects) to EUR 1,542.0 million.

Dräger Group's EBIT rose significantly to a total of EUR 136.7 million, more than four times as high than in the same period in the prior year (9 months 2009: EUR 28.4 million). With 8.9 percent, the EBIT margin also was considerably up on the prior year's figure of 2.1 percent.

 

Reasons for profitability increasing are the continuous positive development in the Americas and Asia/Pacific regions, favorable currency effects and the continuously high percentage of equipment business, which has strong margins, in net sales in the medical division. The turnaround program also had a considerable positive effect. In the first nine months of 2010, it generated additional EUR 36.6 million in savings and efficiency gains (before implementation costs of EUR 0.5 million) compared to the prior year's period (9 months 2009: EUR 35.3 million compared to 2008). Main contributors were savings in Purchasing as well as in Marketing and Sales costs.

 

Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG, explains: We are already certain that 2010 will be the best fiscal year Dräger has ever recorded. We have been working hard to improve our competitive edge compared to 2009, and we have proven that we are quick to catch up."

 

Equity ratio exceeds 30 percent

The company's equity ratio was 32.4 percent at the end of September 2010 (December 31, 2009: 20.9 percent). This increase is mainly due to the capital increase carried out in June 2010 and the positive result of the first nine months.

 

Outlook

Dräger expects net sales growth for fiscal year 2010 in the region of 10 percent (net sales 2009: EUR 1,911 million). Net of currency effects, growth came in around the medium one-digit percentage range. Due to the positive development in the first nine months of 2010, Dräger anticipates an EBIT margin between 8 percent and 9 percent for all of 2010. This forecast includes the impact from the possible cash settled option to the amount of EUR 11.8 million agreed with Siemens. This component will no longer have a negative impact on earnings in the future.

 

In 2011, Dräger will invest even larger sums into research and development, implement projects even more quickly and improve its marketing and sales organization in particular. In addition, the company anticipates that the one-off effects from fiscal year 2010 will not be repeated, including a large number of orders on hand carried over from the previous year, high order intake from large projects, the sale of a deep sea diving system that was fully written off in 2009, the sale of software licenses and the extremely favorable product mix. External factors such as exchange rates are not expected to have the same positive impact in 2011 than in the current year.

 

In view of these facts, Dräger forecasts net sales to increase slightly in 2011 but does not expect for the EBIT margin to exceed that of fiscal year 2010. "In the medium term, we plan to grow faster than the market and achieve a minimum EBIT margin of 10 percent in the long term," comments Stefan Dräger.

 

Key figures for the first nine months of 2010 (in EUR millions)

  Third quarter 2010 Third quarter 2009 Nine months 2010 Nine months 2009 Change

nine months

Net of currency effects
Order intake 519.5 481.7 1,568.4 1,414.5 +10.9 % +6.8 %

Medical division

357.5

323.0

1,056.3

928.4

+13.8 %

+9.9 %

Safety division

167.7

166.1

532.8

506.0

+5.3 %

+0.9 %

             
Net sales 525.3 454.4 1,542.0 1,348.3 +14.4 % +10.2 %

Medical division

351.7

293.5

1,028.9

871.1

+18.1 %

+14.2 %

Safety division

178.6

167.7

531.6

496.4

+7.1 %

+2.7 %

             
EBIT[1] 34.1 13.3 136.7 28.4 +381.3 %  

Medical division

35.2

9.1

128.2

20.2

+534.7 %

 

Safety division

17.8

10.1

47.1

28.1

+67.6 %

 

             
EBIT margin 6.5 % 2.9 % 8.9 % 2.1 %    
Earnings after income taxes 14.3 3.5 70.2 4.8    
EPS[2] preferred share 0,75 0,14 4,27 0,01    
EPS[2] common share 0,73 0,12 4,22 -0,04    

[1] EBIT = Earnings before interest and taxes

[2] EPS = Earnings per share (in €)

 

Disclaimer

This press release contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this report. You will find all other financial dates on our website at www.draeger.com under Investor Center/Financial Calendar.

 

 

Contact

           

Corporate Communications:

Burkard Dillig

Tel. +49 451 882-2185

burkard.dillig@draeger.com

 

Investor Relations:

Vanina Herbst

Tel. +49 451 882-2685

vanina.herbst@draeger.com

 

Drägerwerk AG & Co. KGaA     

Moislinger Allee 53-55

23558 Lübeck, Germany

www.draeger.com

HUG#1458841

Press release (PDF)

--- End of Message ---

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55 Lübeck Germany

Listed: Freiverkehr in Börse Stuttgart,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse,

Regulierter Markt in Bayerische Börse München,

Regulierter Markt in Börse Berlin,

Regulierter Markt in Hanseatische Wertpapierbörse zu Hamburg,

Regulierter Markt in Börse Düsseldorf,

Regulierter Markt in Niedersächsische Börse zu Hannover;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
18 feb
NOVO-B
Når ens hustru har lidt voldsomt under diabetes  og dens bivirkninger tiltagende gennem 25 år, så er..
34
19 feb
 
Jeg tager hatten for dit velbegrunede og fyldestgørende indlæg til debatten. Det kunne mange lære af..
32
16 feb
NOVO-B
@ Investor1 Jeg er hverken for eller imod hvad du skriver, men jeg har nu i gennem næsten et år løbe..
30
21 feb
GEN
Det er altid rart at møde et ungt menneske, der har potentiale til at blive klogere.
24
21 feb
GEN
Du bliver da dummere og dummere at høre på 
21
17 feb
MAERSK-B
Jeg er i mit vemodige hjørne i dag, for det er den første dag i over 25 år, hvor jeg ikke kan kalde ..
20
16 feb
NOVO-B
Din og Investor1's totale fejlvurdering af både Zealand og Novo har desværre udviklet sig til et per..
20
17 feb
E:QEC
Med fare for en gentagelse, så vil jeg alligevel melde at Canada er i fuld gang med at omstille sig ..
18
17 feb
NOVO-B
@alpenyt Tror bare jeg vil kalde dig for Wiki(pedia) fra nu af :) Du burde skrive en artikel i kvart..
17
16 feb
NOVO-B
Jeg deltager, modsat dig, med argumenter og fakta, du er blot personfnidrer, fordi du ikke kan forst..
15

Aktier/middag: Genmab buldrer frem med WDH og ISS som følgesvende

22-02-2018 11:40:57
Biotekselskabet Genmab ligger helt i top i det danske eliteindeks torsdag middag efter at have præsenteret regnskab onsdag aften. Også ISS og William Demant, der begge kom med regnskab for fjerde kvartal torsdag morgen, er med i toppen.Men det er onsdagens regnskab fra Genmab, der trækker den helt store opmærksomhed, efter at biotekselskabet gjorde markedets bekymringer over en mulig skuffende pro..

ISS: Salget vokser mens bundlinjen skrumper

22-02-2018 08:39:00
ISS kan se bundlinjen falde tilbage i 2017 sammenlignet med i 2016, selvom selskabet er vokset på salget.Omsætningen i selskabet voksede til 79.912 mio. kr. i 2017, mens omsætningen udgjorde 78.658 mio. kr. i 2016.Omvendt steg nettoresultatet i 2017 til 2007 mio. kr. mod 2220 mio. kr. året før.Af regnskabet fremgår det, at årsagen til at bundlinjen ikke vokser med toplinjen, blandt andet er ekster..

Novo Nordisk: Ozempic optaget på stor indkøbsforenings tilskudsliste

21-02-2018 15:39:04
Novo Nordisks nylancerede ugentlige GLP-1-analog Ozempic er blevet optaget på den amerikanske indkøbsforening Express Scripts nationale tilskudsliste, der gælder for en lang række sygekasser i 2018.Det bekræfter Novo Nordisk over for Ritzau Finans.Optagelsen er et vigtigt skridt i Novos arbejde med at indgå kontrakter med de store indkøbsforeninger, der står for sygekassernes indkøb og også rådgiv..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/åbning: Genmab brager frem og trækker eliteindekset i plus
2
Genmab/CEO: Ro på - Darzalex-salget skal ses på kvartalsbasis
3
Novo/Sydbank: Succes-forsøg kan ende med blockbustertablet
4
Aktier/tendens: Genmab, ISS og William i fokus i rød handelsstart
5
Novo: Første tabletstudie med Semaglutid er en succes - NY

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. februar 2018 21:37:39
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseBuild_20180222.1 - EUROWEB7 - 2018-02-22 21:37:39 - 2018-02-22 21:37:39 - 1 - Website: OKAY